Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a profile of its use in the USA

AbstractThe antibody-drug conjugate (ADC) loncastuximab tesirine (loncastuximab tesirine-lpyl, Zynlonta®), is a useful option for third-line and subsequent treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Loncastuximab tesirine comprises a humanized anti-CD19 antibody linked to a pyrrolobenzodiazepine (PBD) dimer cytotoxic alkylating agent. It is the first CD19-targeted ADC approved for third-line and subsequent treatment of relapsed or refractory large B-cell lymphoma, DLBCL not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma. In the pivotal phase II LOTIS-2 trial, loncastuximab tesirine as monotherapy produced an overall response rate (ORR) of 48% in heavily pre-treated patients with relapsed or refractory DLBCL, some of whom had previously received chimeric antigen receptor (CAR)-T cell therapy or hematopoietic stem cell transplantation (HSCT). The adverse event profile of loncastuximab was consistent with that seen with other PBD-based treatments, characterized by fluid overload and elevated γ-glutamyl transferase levels.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research